Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota

Ferreira, Rui M.; Pereira-Marques, Joana; Pinto-Ribeiro, Inês; Costa, José Luís; Carneiro, Fátima; Figueiredo, Céu

doi:10.1136/gutjnl-2017-314205

Cited by 494 publications

(646 citation statements)

References 44 publications

(42 reference statements)

Supporting

Mentioning

559

Contrasting

Unclassified

Order By: Relevance

“…Increased diversity (richness and phylogenetic diversity;) or no differences (evenness and Shannon; in cancer in comparison with patients with functional dyspepsia or chronic gastritis were noted. However, the two studies with the largest patient numbers reported decreased diversity in cancer or intestinal metaplasia in comparison with the chronic gastritis microbiota. The gastric microbial community profiles in cancer were significantly different from those of noncancerous stomachs .…”

Section: Resultsmentioning

confidence: 94%

“…Specific microbial groups were rarely found exclusively in one diagnostic group. For instance, a Portuguese cohort of gastric cancer compared to gastritis patients showed that cancer patients had increased abundance of several microbial groups including Achromobacter . However, Achromobacter species were completely absent in a Chinese validation cohort, indicating that geographical origin might have similar if not stronger impact on the gastric microbiota composition than the pathology itself.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review: gastric microbiota in health and disease

Rajilić‐Stojanović¹,

Figueiredo²,

Smet³

et al. 2020

Aliment Pharmacol Ther

Self Cite

121

112

View full text Add to dashboard Cite

Background Helicobacter pylori is the most infamous constituent of the gastric microbiota and its presence is the strongest risk factor for gastric cancer and other gastroduodenal diseases. Although historically the healthy stomach was considered a sterile organ, we now know it is colonised with a complex microbiota. However, its role in health and disease is not well understood. Aim To systematically explore the literature on the gastric microbiota in health and disease as well as the gut microbiota after bariatric surgery. Methods A systematic search of online bibliographic databases MEDLINE/EMBASE was performed between 1966 and February 2019 with screening in accordance with Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. Randomised controlled trials, cohort studies and observational studies were included if they reported next‐generation sequencing derived microbiota analysis on gastric aspirate/tissue or stool samples (bariatric surgical outcomes). Results Sixty‐five papers were eligible for inclusion. With the exception of H pylori‐induced conditions, overarching gastric microbiota signatures of health or disease could not be determined. Gastric carcinogenesis induces a progressively altered microbiota with an enrichment of oral and intestinal taxa as well as significant changes in host gastric mucin expression. Proton pump inhibitors usage increases gastric microbiota richness. Bariatric surgery is associated with an increase in potentially pathogenic proteobacterial species in patient stool samples. Conclusion While H pylori remains the single most important risk factor for gastric disease, its capacity to shape the collective gastric microbiota remains to be fully elucidated. Further studies are needed to explore the intricate host/microbial and microbial/microbial interplay.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Systematic review: gastric microbiota in health and disease

Rajilić‐Stojanović¹,

Figueiredo²,

Smet³

et al. 2020

Aliment Pharmacol Ther

Self Cite

121

112

View full text Add to dashboard Cite

show abstract

“…However, analysis of cancer‐specific enrichment and depletion at the taxonomic level yielded conflicting results between the two studies, possibly reflecting different geographic, ethnic and dietary backgrounds of the study populations. Furthermore, comparing the study results with the PPI‐associated changes to the gastric microbiota reviewed here, not a single concordantly regulated taxon can be identified …”

Section: Discussionmentioning

confidence: 99%

Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract—evidence from next‐generation sequencing studies

Macke

Schulz

Koletzko

et al. 2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Proton pump inhibitors (PPI) are widely used to treat acid-related disorders of the upper gastrointestinal tract. However, large observational studies have raised concerns about PPI-associated adverse events. In recent years, data from next-generation sequencing studies suggested that PPIs affect the composition of the intestinal microbiota, while a balanced gut microbiome is essential for maintaining health.Aim: To review the available evidence from next-generation sequencing studies on the effect of PPIs on the intestinal microbiome and to discuss possible implications of PPI-induced dysbiosis in health and disease.Methods: A systematic review was conducted following the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. A PubMed query yielded 197 results. 19 publications met the prespecified eligibility criteria.Results: Twelve observational study cohorts with 708 PPI users and 11 interventional cohorts with 180 PPI users were included in the review. In most studies, PPI treatment did not affect microbiological richness and diversity, but was associated with distinct taxonomic alterations: In the upper gastrointestinal tract, PPI users showed overgrowth of orally derived bacteria, mostly Streptococcaceae (findings based on six independent cohorts with 126 PPI users). In faecal samples, PPIs increased multiple taxa from the orders Bacillales (eg, Staphylococcaceae), Lactobacillales (eg, Enterococcaceae, Lactobacillaceae, Streptococcaceae) and Actinomycetales (eg, Actinomycetaceae, Micrococcaceae), the families Pasteurellaceae and Enterobacteriaceae and the genus Veillonella. Taxa decreased by PPIs include Bifidobacteriaceae, Ruminococcaceae, Lachnospiraceae and Mollicutes (findings in faecal samples based on 19 independent cohorts with 790 PPI users). Conclusion: PPI use is associated with moderate alterations to upper and distal gut microbiota. The available data suggest that PPI-induced hypochlorhydria facilitates colonization of more distal parts of the digestive tract by upper gastrointestinal microbiota. MACKE Et Al 1 | INTRODUC TI ON: G A S TRI C ACID INHIB ITI ON AND ADVER S E EFFEC TS OF PPIS Gastric acid eliminates microorganisms, promotes the digestive process and facilitates the absorption of iron, calcium and vitamin B12. However, gastric acid also contributes to the development of mild and severe gastroduodenal pathologies. Proton pump inhibitor (PPIs) are the most effective therapy of acid-related diseases and are among the most commonly used drugs. 1 While generally considered a safe therapy, PPIs have been associated with numerous adverse effects in population-based observational studies conducted in recent years. These include cardiovascular and kidney disease, micronutrient deficiencies and osteoporosis, cognitive impairment and death. 2Most studies are retrospective and not hypothesis-driven in design, might be subject to significant confound and thus they cannot establish causality. 2,3 This is also the case for a recent study on ...

show abstract

“…Carcinogenesis of gastric cancers is associated with H. pylori and some oral microbiota including Fn , Parvimonas micra and Peptostreptococcus stomatis . Significant enrichment of Peptostreptococcus stomatis , Parvimonas micra , Streptococcus anginosus , Dialister pneumosintes , Slackia exigua, Clostridium colicanis and Fn and depletion of Helicobacterium was observed in gastric cancer, and alterations in bacterial diversity and abundance in patients with gastric cancer revealed a dysbiotic microbial community with prediction potential . Recently, incremental data has demonstrated that eradication treatment for H. pylori could reduce the risk of gastric cancer .…”

Section: Fmt As a Possible Therapy For Various Type Of Cancers And Camentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

223

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota

Cited by 494 publications

References 44 publications

Systematic review: gastric microbiota in health and disease

Systematic review: gastric microbiota in health and disease

Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract—evidence from next‐generation sequencing studies

Fecal microbiota transplantation in cancer management: Current status and perspectives

Contact Info

Product

Resources

About